To be closer to business partners located in the UK
Selvita, a drug discovery company with offices in the US and Poland, is opening its first office in the United Kingdom.
Based in Cambridge, the new office will support ongoing projects for Selvita's customers from the UK and Northern Ireland, as well as seeking new collaboration opportunities in the area of integrated drug discovery services with pharma and biotech companies in the region.
Selvita Ltd will be focused on supporting and developing business relationships with local partners whereas Selvita’s laboratories remain in Krakow, Poland.
'We decided to establish direct presence in the UK, in order to be closer to our business partners located in the UK,' said Dr Milosz Gruca, Chief Executive at Selvita UK.
Selvita currently employs more than 230 chemists and molecular biologists. The company offers integrated drug discovery services, medicinal chemistry, custom synthesis, in vitro biology services, protein production and analytical services. It also conducts its own small-molecule research programmes in oncology. Clients include many medium and large pharmaceutical and biotechnology companies from the US, Western and Central Europe, Israel, Japan and Brazil.
Alicja Malysiak, Vice President of Sales at Selvita UK, added: 'I am excited that Selvita is establishing its presence in Cambridge – home to the leading scientific organisations. This step will allow us to become more visible on the local market and remain at full disposal of our UK-based customers. I strongly believe that Selvita can become a valuable partner for many leading pharmaceutical and biotechnology companies in the UK and Northern Ireland.'